Susquehanna International Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-335,500
| Closed | -$8.09M | – | 13714 |
|
|
2023
Q1 | $8.09M | Sell |
335,500
-203,600
| -38% | -$2.55M | ﹤0.01% | 2761 |
|
|
2022
Q4 | $5.7M | Buy |
539,100
+400,800
| +290% | +$3.23M | ﹤0.01% | 3039 |
|
|
2022
Q3 | $622K | Buy |
138,300
+18,000
| +15% | +$82K | ﹤0.01% | 7886 |
|
|
2022
Q2 | $481K | Sell |
120,300
-52,700
| -30% | -$250K | ﹤0.01% | 8359 |
|
|
2022
Q1 | $1.27M | Buy |
+173,000
| New | +$1.03M | ﹤0.01% | 6549 |
|
|
2021
Q4 | – | Sell |
-270,200
| Closed | -$1.73M | – | 14232 |
|
|
2021
Q3 | $1.73M | Buy |
270,200
+198,500
| +277% | +$1.28M | ﹤0.01% | 6162 |
|
|
2021
Q2 | $604K | Sell |
71,700
-55,900
| -44% | -$451K | ﹤0.01% | 9143 |
|
|
2021
Q1 | $1.34M | Buy |
+127,600
| New | +$1.8M | ﹤0.01% | 6957 |
|
|
2020
Q4 | – | Sell |
-149,300
| Closed | -$1.92M | – | 11933 |
|
|
2020
Q3 | $1.92M | Sell |
149,300
-172,100
| -54% | -$2.17M | ﹤0.01% | 4708 |
|
|
2020
Q2 | $4.54M | Buy |
321,400
+286,300
| +816% | +$3.61M | ﹤0.01% | 3139 |
|
|
2020
Q1 | $323K | Sell |
35,100
-4,900
| -12% | -$63.2K | ﹤0.01% | 7837 |
|
|
2019
Q4 | $596K | Buy |
40,000
+25,900
| +184% | +$231K | ﹤0.01% | 6603 |
|
|
2019
Q3 | $96K | Buy |
+14,100
| New | +$143K | ﹤0.01% | 9578 |
|
Other funds holding PRVB
Susquehanna International Group's PRVB Position: Q2 2023 in Review
Susquehanna International Group sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 363,758 shares — an estimated $8.77M sold.
Susquehanna International Group first reported a position in PRVB in Q2 2019 and held it in 16 quarters. The position peaked at $8.77M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Susquehanna International Group reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Susquehanna International Group sold 363,758 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $8.77M.
- Susquehanna International Group first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- Susquehanna International Group's Provention Bio, Inc. Common Stock position peaked at $8.77M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.